2016
DOI: 10.1016/j.bmc.2016.08.044
|View full text |Cite
|
Sign up to set email alerts
|

Identification of indole scaffold-based dual inhibitors of NOD1 and NOD2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
19
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 18 publications
(22 citation statements)
references
References 59 publications
3
19
0
Order By: Relevance
“…Suppressing NOD2 with NOD2 siRNA decreases autophagy induced by M. ovipneumoniae. NOD-IN-1 is a mixed inhibitor of NOD1 and NOD2 (25). To further verify the impact of NOD2 on M. ovipneumoniae-induced macrophage autophagy, RAW 264.7 cells were transfected with small interfering (siRNA)-control (NC) or siRNA-NOD2 and then infected with M. ovipneumoniae for 12 h. A decrease in NOD2 was observed after transfection with siRNA-NOD2-1 and siRNA-NOD3-3.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Suppressing NOD2 with NOD2 siRNA decreases autophagy induced by M. ovipneumoniae. NOD-IN-1 is a mixed inhibitor of NOD1 and NOD2 (25). To further verify the impact of NOD2 on M. ovipneumoniae-induced macrophage autophagy, RAW 264.7 cells were transfected with small interfering (siRNA)-control (NC) or siRNA-NOD2 and then infected with M. ovipneumoniae for 12 h. A decrease in NOD2 was observed after transfection with siRNA-NOD2-1 and siRNA-NOD3-3.…”
Section: Resultsmentioning
confidence: 99%
“…MDP is an activator of NOD2, and NOD-IN-1 is a potent mixed inhibitor of NOD1 and NOD2 ( 25 ). To further test the involvement of NOD2 in M. ovipneumoniae -induced autophagy, we measured the colocalization of M. ovipneumoniae and LC3 in RAW 264.7 cells treated with MDP or NOD-IN-1.…”
Section: Resultsmentioning
confidence: 99%
“…Therefore, NOD receptors appear to be potentially important targets of therapeutic intervention in sepsis and septic shock. Presently, antagonists of NOD1 and NOD2 are being developed . Most of these compounds are derivatives of heterocyclic bicyclic compounds such as indole, purine, or benzimidazole .…”
Section: Potential Clinical Relevance Of Nod‐tlr Synergymentioning
confidence: 99%
“…Presently, antagonists of NOD1 and NOD2 are being developed . Most of these compounds are derivatives of heterocyclic bicyclic compounds such as indole, purine, or benzimidazole . Some of them are dual NOD1/NOD2 antagonists, whereas others are selective towards NOD1 or NOD2 .…”
Section: Potential Clinical Relevance Of Nod‐tlr Synergymentioning
confidence: 99%
See 1 more Smart Citation